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a b s t r a c t
Crohn’s disease (CD) presents a great challenge regarding treatment, considering that the 
best drugs available have very limited effectiveness. 
Objective: To analyze the characteristics between groups of patients with Crohn’s disease 
who had response versus had not/lost response to treatment with anti-TNF. 
Method: Retrospective study of patients with CD treated with IFX or ADA. 
Results: We studied 72 patients with mean age of 35 years; 45 of them were treated with 
infl iximab and 27 with adalimumab; 90% of women were respondents, compared to 10% 
who were not respondents/lost response, and 60% of men were respondents versus 40% 
who were not respondents/lost response; there was no difference between IFX and ADA 
with respect to response; 48 patients were < 40  and 24 > 40 years old. Of those who had < 
40 years, 37 were respondents, compared to 11 who were not respondents/lost response. 
Of those with > 40 years, 16 were respondents versus 8 who were not respondents/lost 
response; patients under 2 years of diagnosis had a better response than those with two to 
fi ve years of symptoms, and these latter exhibited a better response than those with more 
than fi ve years of diagnosis. 
Conclusion: The observed characteristics of response to treatment of CD with anti-TNF were: 
association to azathioprine, female gender, age < 40 years and less than two years of diagnosis.
© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. 
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Análise dos fatores relacionados à resposta e à ausência/perda de 
resposta ao anticorpo antifator de necrose tumoral-alfa no tratamento 
da doença de Crohn
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r e s u m o
A doença de Crohn (DC) apresenta um grande desafio quanto ao seu tratamento, consi-
derando-se que os melhores medicamentos disponíveis têm eficácia bastante limitada. 
Objetivo: Analisar as características entre os grupos de pacientes com DC que respon-
deram e os que não responderam ou perderam a resposta ao tratamento com anti-TNF. 
Método: Estudo retrospectivo de pacientes com DC que fizeram uso de IFX ou ADA. 
Resultados: Foram estudados 72 pacientes com média de idade de 35 anos; 45 foram tra-
tados com adalimumabe e 27 com infliximabe; 90% das mulheres tiveram resposta, con-
tra 10 que não tiveram/perderam resposta; dos homens, 60% tiveram resposta contra 
40% que não tiveram/perderam resposta; não houve diferença entre IFX e ADA quanto 
à resposta; 48 tinham menos de 40 anos e 24 mais de 40 anos. Dos com < 40 anos, 37 ti-
veram resposta, contra 11 que não tiveram/perderam resposta. Daqueles com > 40 anos, 
16 tiveram resposta contra 8 que não tiveram/perderam resposta; pacientes com menos 
de 2 anos de diagnóstico tiveram melhor resposta do que aqueles com dois a cinco anos 
de sintomas; e estes tiveram melhor resposta que aqueles com mais de cinco anos de 
diagnóstico. 
Conclusão: As características observadas de melhor resposta ao tratamento da DC com 
anti-TNF foram associação com azatioprina, gênero feminino, idade menor de 40 anos e 
menos de dois anos de diagnóstico.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. 
Introduction
Crohn's disease (CD) has been a major challenge for physicians 
treating inflammatory bowel diseases. Since its description in 
1932, by Burrill Crohn et al.,1 a lot of information was obtained 
in relation to its pathophysiology and therapeutics, with more 
significant advances in the last two decades with regard to 
treatment. However, one should take into account that there is 
still much to be discovered, since our best combination therapy 
benefits persistently no more than 40% of patients.2
If on one hand we must seek – and we are seeking – new 
drugs that improve the therapeutic efficacy, on the other hand 
we should strive to achieve more efficient methods to employ 
our present knowledge, but with strategies to achieve better 
results. In this respect, we must emphasize the great contribu-
tion of Colombel et al.,3 who were more successful with the 
combination of infliximab and azathioprine versus monother-
apy with each of these drugs.
The evaluation of the presence of anti-biological agent anti-
bodies and the dosage of circulating levels of these drugs have 
been shown to be of great value, but such procedures are not 
yet widespread in most Brazilian cities, due to their cost. 
The evaluation of results obtained from the use of anti-TNF 
therapy may be helpful, if it is shown that in certain indications 
for its use in DC patients a better response to one or another 
biological agent is obtained. Currently, the indications for these 
drugs in DC are the same.4
Thus, the objective of this trial was to analyze the char-
acteristics between groups of patients who had responded 
versus did not respond or lost response to a treatment with 
anti-TNF.
Method
A retrospective study of medical records of patients from the 
Inflammatory Bowel Diseases Outpatient Service, Hospital Uni-
versitário Maria Aparecida Pedrossian, Universidade Federal de 
Mato Grosso do Sul, Hospital Regional de Mato Grosso do Sul, 
and at the private practice of the author.
Patients with Crohn's disease who were referred and made 
use of anti-TNF agents were included. All patients included were 
previously investigated for presence of TB and hepatitis B.
The study period was from June 2000 to July 2013. The anti-
TNF agents were used at recommended doses and intervals: in-
fliximab (IFX) 5 mg/kg at weeks 0, 2 and 6, with maintenance at 
every 8 weeks; and adalimumab (ADA) 160 mg on week 0, 80 mg 
on week 2 and 40 mg at every 2 weeks.
Patients with perianal fistulas were treated by curettage and 
placement of a seton, with successive changes, if necessary, un-
til it was possible to remove the drain. On average, the biological 
therapy in these patients was introduced one week after surgery.
We considered as a clinical response to anti-TNFa the reduc-
tion of Crohn's disease activity index of (DCAI) ≥ 100 points5 and, 
in cases of perianal fistulas, absence of pain and secretion for 
more than six months.
The results were statistically analyzed by Student's t test 
and chi-square test, and p < 0.05 was considered statistically 
significant.
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Table 1 – Indications for the use of anti-TNF agents in 
the group studied.
Indications Number of patients
Age <40 years 45
Perianal fistula 30
Extensive disease in small intestine 26
Intractability 24
Stenosing disease 9
Extra-intestinal disease 4
Deep ulcers at colonoscopy 4
Corticodependence 3
Rectovaginal fistula 2
Enteroenteric fistula 2
Growth deficit 2
Toxic megacolon 1
Some patients had more than one indication.
Results
72 patients, 40 (55%) male and 32 (45%) female, were studied. 
The age ranged from 14 to 59 years old, with a mean of 35 years. 
The main indications for the use of anti-TNF agents are listed 
in Table 1.
The choice of anti-TNF agent was based on preference of pa-
tients and availability of the agent, similarly to information from 
the literature on the subject.6,7 Of the 72 patients, 45 (62.5%) were 
treated with adalimumab and 27 (37.5%) with infliximab (Fig. 1).
In our population of 72 patients, 53 remained with the same 
agent originally prescribed, considering that they obtained clini-
cal response. On average, the time of drug use was 18 months, 
ranging from one to 60 months.
Of these 53, eight patients were not treated with immunosup-
pression in combination with anti-TNF, considering that many 
of these individuals had their treatment started before there 
was medical evidence favouring this therapeutic approach.3 The 
remaining 45 patients made  use of anti-TNF in combination 
with azathioprine (AZA) (2-3 mg/kg/day),8 but five of them dis-
continued the use of this agent, due to intolerance. Therefore, 40 
(75%) patients remained in the combined treatment: 23 on ADA 
+ AZA and 17 on IFX + ADA. Respecting to the 19 patients who 
did not respond/lost response, 11 (58%) had an immunosuppres-
sive associated (Fig. 2).
Women showed better response to anti-TNF therapy than 
men, since that 29 women (90% of women) kept using it versus 
24 men (60% of men) (Fig. 3).
When the response in relation to anti-TNF agent was ana-
lyzed, there was no statistically significant difference between 
groups. Of the 45 patients treated with ADA, 33 had a response 
(73%) and 12 did not respond/lost response (27%). Of those who 
received IFX, 20 had a response (74%) and seven did not respond/
lost response (26%) (Fig. 4); p = 0.5.
Forty-eight patients were < 40 and 24 > 40 years old. Of those 
who were <40 years, 37 had a response, compared with 11 who 
did not respond/lost response. Of those with > 40 years, 16 had 
a response, against eight who did not respond/lost response 
(Fig. 5); p = 0.000358.
Fig. 1 – Anti-TNF agents used according to preference of 
patients. ADA, adalimumab; IFX, infliximab.
50.0
37.5
25.0
12.5
Fig. 2 – Comparison between groups of patients who had a 
clinical response to anti-TNF and who lost/had no answer for 
the use of an immunosuppressant (azathioprine) associated. 
In the group which had response, comparison between IFX + 
AZA and ADA + AZA versus IFX and ADA, p = 0.0000193, while 
among those who lost/had no answer, comparison between 
IFX + AZA and ADA + AZA versus IFX + AZA, p = 0.30550. IFX, 
infliximab; AZA, azathioprine; ADA, adalimumab.
Fig. 3 – Relationship among gender and groups of patients 
who had or had not/lost response to anti-TNF.  
p = 0.0000914.
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When we analyzed the interval between the first symp-
toms of AD and the beginning of biological therapy, a statis-
tically significant difference between groups was perceived. 
Among those who had a clinical response, 28 (53%) initiated 
the use of anti-TNF with less than two years of symptoms, 17 
(32%) between two and five years and eight (15%) with more 
than five years. Of those who did not respond/lost response, 
nine (47%) started treatment with less than two years of clini-
cal manifestations, six (32%) between two and five years and 
four (21%) after five years (Fig. 6).
Discussion
The selection of the anti-TNF agent was based on patient pref-
erence and availability of access to hospital. A study with a 
larger number of patients to evaluate this criterion examined 
patients with rheumatoid arthritis and has shown a slight 
preference for the use of intravenous anti-TNF.6 Specifically in 
DC, the CHOOSE study showed a different result, with greater 
preference for subcutaneous anti-TNF (adalimumab, 36%, and 
certolizumab pego 128%), compared to 25% with preference by 
intravenous administration (infliximab).7 Vavricka et al. report-
ed that, when questioned about the reason for the choice of 
subcutaneous anti-TNF, 69% of patients stated that the ease of 
use was determinant. In the present study it was also observed 
that there was a greater preference for subcutaneous anti-TNF, 
probably due to its greater practicality.
Since the publication of Colombel et al.3 demonstrating 
greater efficacy of infliximab in combination with azathio-
prine, it became almost mandatory to use, when possible, 
the so-called combotherapy to ensure improved response to 
anti-TNF. The authors believe that this combination can pro-
mote lower immunogenicity, so as to allow the efficacy of the 
drugs for a longer time, besides the very action of azathio-
prine, which is extremely beneficial in many cases of Crohn's 
disease. This has also been subsequently confirmed by other 
authors.9 In our study it was also observed that when the 
pharmacological combination of anti-TNF with an immu-
nosuppressant was used, this latter drug could be kept in a 
larger number of patients, since 75% of patients who had a 
response to anti-TNF were also in use of azathioprine, against 
58% of those who lost or had no response to this medication.
It seemed to us quite interesting to observe that women 
were more responsive than men to the use of biologicals. 
There is little information on this topic in the medical liter-
ature. However, in a study of gender differences in response 
to treatment of DC performed in children, Lee et al.10 were 
not able to identify differences in response to treatment 
with anti-TNF among boys and girls. In adults with luminal 
or fistulizing CD, Sprakes et al.11 obtained findings opposite 
to our results, with male gender as a predictor of good re-
sponse to IFX.
No difference in response to treatment was observed com-
paring patients using ADA and IFX. Kestens et al.12 recently 
published a study comparing IFX and ADA in patients without 
prior treatment with anti-TNF; these authors also were not 
Fig. 4 – Evaluation of clinical response with respect to anti-
TNF used. p = 0.05. ADA, adalimumab; IFX, infliximab.
Fig. 5 – Evaluation of the interval between the onset of 
symptoms of DC using anti-TNF in patients who had a 
response and those who had not/lost response. p = 0.003 
between <2 years and 2-5 years; p = 0.004 between 2-5 
years and >5 years.
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Fig. 6 – Comparison between groups that had response 
versus had not/lost response, with respect to age.  
p = 0.0003.
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able to demonstrate differences between these two agents 
with respect to efficacy in CD.
A better response to anti-TNF in patients less than 40 years 
versus older patients was observed. Weiss et al.13 found no dif-
ference in response to treatment with anti-TNF with respect 
to the age of patients in a recently published study, in which 
the authors analyzed the difference in response regarding age.
Currently, the time elapsed between the onset of symp-
toms and the treatment of DC with anti-TNF has been ap-
preciated, because the shorter this period, the better the re-
sponse to this therapeutic agent.14 The same situation was 
observed in the present study, because the group treated with 
less than two years of diagnosis obtained better results than 
those patients treated with a diagnosis established between 
2-5 years, and this latter group obtained better results versus 
the group with > 5 years of diagnosis.
Conclusion 
The observed characteristics of better response to treatment of 
DC with anti-TNF were associated with azathioprine, female 
gender, age < 40 years and less than two years of diagnosis.
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